Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,229,595
  • Shares Outstanding, K 70,469
  • Annual Sales, $ 51,840 K
  • Annual Income, $ -370,640 K
  • 60-Month Beta 1.64
  • Price/Sales 62.78
  • Price/Cash Flow N/A
  • Price/Book 4.55
Trade BEAM with:

Options Overview Details

View History
  • Implied Volatility 81.40% ( +4.30%)
  • Historical Volatility 86.33%
  • IV Percentile 33%
  • IV Rank 28.77%
  • IV High 125.67% on 05/12/22
  • IV Low 63.51% on 12/22/21
  • Put/Call Vol Ratio 0.43
  • Today's Volume 403
  • Volume Avg (30-Day) 493
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 10,733
  • Open Int (30-Day) 12,418

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.32
  • Number of Estimates 7
  • High Estimate -1.00
  • Low Estimate -1.57
  • Prior Year -0.85
  • Growth Rate Est. (year over year) -55.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.71 +34.89%
on 11/07/22
54.30 -13.78%
on 11/15/22
+3.22 (+7.39%)
since 11/02/22
3-Month
34.71 +34.89%
on 11/07/22
61.40 -23.75%
on 09/15/22
-5.86 (-11.12%)
since 09/02/22
52-Week
27.77 +68.60%
on 05/12/22
88.18 -46.90%
on 12/22/21
-25.74 (-35.47%)
since 12/02/21

Most Recent Stories

More News
A Sitcom Character Inspired This Investor

Plus, a look at the "Buffett premium" that investors give to Berkshire Hathaway stock.

BRK.AX : 0.012 (+9.09%)
TGT : 164.16 (-0.53%)
DIS : 99.43 (+0.85%)
V : 217.66 (+0.30%)
HD : 327.99 (+0.28%)
LOW : 214.84 (-0.30%)
CHWY : 44.92 (+1.29%)
NFLX : 320.41 (+1.09%)
COST : 494.53 (-1.85%)
CMCSA : 35.86 (-1.16%)
AMZN : 94.13 (-1.43%)
BEAM : 46.82 (+2.16%)
Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the company's progress with its collaboration deals and the performance of its business units.

BAYRY : 14.5100 (-0.21%)
BEAM : 46.82 (+2.16%)
EBS : 12.00 (+1.61%)
DNA : 1.9900 (+0.51%)
Why Beam Therapeutics Stock Is Falling Today

Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today.

BEAM : 46.82 (+2.16%)
Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

PRGO : 31.94 (-0.62%)
BEAM : 46.82 (+2.16%)
EBS : 12.00 (+1.61%)
ARVN : 41.39 (+4.13%)
AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

AZN : 68.47 (+0.19%)
MRK : 110.04 (+0.22%)
BEAM : 46.82 (+2.16%)
EBS : 12.00 (+1.61%)
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -20% and 51.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

BEAM : 46.82 (+2.16%)
AFMD : 2.09 (+2.45%)
The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics

CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.

BEAM : 46.82 (+2.16%)
SRPT : 126.25 (+2.66%)
EDIT : 10.25 (+1.89%)
CRSP : 54.50 (+0.29%)
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, which have the potential to gain from their promising gene therapy pipeline candidates.

BEAM : 46.82 (+2.16%)
SRPT : 126.25 (+2.66%)
EDIT : 10.25 (+1.89%)
CRSP : 54.50 (+0.29%)
Why Beam Therapeutics Stock Rocketed Higher This Week

The biotech's share price has been on a wild ride in 2022.

BEAM : 46.82 (+2.16%)
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down

Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.

AZN : 68.47 (+0.19%)
NVAX : 16.52 (-1.96%)
BEAM : 46.82 (+2.16%)
APLS : 50.63 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 53.34
2nd Resistance Point 50.37
1st Resistance Point 48.60
Last Price 46.82
1st Support Level 43.86
2nd Support Level 40.89
3rd Support Level 39.12

See More

52-Week High 88.18
Fibonacci 61.8% 65.10
Fibonacci 50% 57.97
Fibonacci 38.2% 50.85
Last Price 46.82
52-Week Low 27.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar